Drug Trial Radar · NCT07900568
Study of HXN-1013 in Healthy Participants and Participants With Mild-to-Moderate Asthma
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Feb 15, 2028
Study completion May 30, 2028
Sponsor
- Lead sponsor
- Helixon Biotechnology (Suzhou) Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I, randomized, double-blind, placebo-controlled, single ascending dose study evaluating HXN-1013 in healthy participants and participants with mild-to-moderate asthma.
Conditions
- Health Adults
- Asthma
Interventions
HXN-1013Drug
Participants will receive a single subcutaneous dose of HXN-1013.
PlaceboDrug
Participants will receive a single subcutaneous dose of placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: Up to day 141
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Veritus Research
Bayswater, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.